Abstract
Currently, the treatment of childhood medulloblastoma (MB) is tailored to risk groups defined by clinical parameters. Growing evidence of tumoral heterogeneity is apparent as response remains varied and unpredictable based on current treatment strategies, indicating the lack of understanding of the elusive biology that drives oncogenesis of these tumors. Advances in genomic technologies are revealing newer insights into the molecular pathogenesis of MB. Utilization of the genomic machinery has enabled the definition of new molecular markers and signaling pathways, resulting in a paradigm shift in the classification of childhood MB. Recent focus into the postgenomic era has revealed varied perturbations in the epigenetic machinery in these subtypes as likely predictive biomarkers and potential therapeutic targets. Ahead lies the task and challenge in the ability to comprehensively evaluate all these data, which could provide clues to profile the next-generation clinical trials combining conventional with molecularly targeted novel therapies.
Original language | English (US) |
---|---|
Pages (from-to) | 637-645 |
Number of pages | 9 |
Journal | Future Oncology |
Volume | 10 |
Issue number | 4 |
DOIs | |
State | Published - Mar 2014 |
Keywords
- cerebellum
- epigenetics
- medulloblastoma
- molecular classification
- mutation
- targeted therapy
ASJC Scopus subject areas
- Oncology
- Cancer Research